论文部分内容阅读
目的探讨口吸及鼻吸激素对过敏性鼻炎-哮喘综合症(CARAS)患者临床症状及生存质量的影响。方法 55例过敏性鼻炎-哮喘综合症患者被随机分为两组,鼻吸组27例,给予丙酸氟替卡松鼻喷雾剂,早上每个鼻孔各2次,晚上每个鼻孔各3次,鼻腔吸入,每喷50μg;口吸组28例,给予丙酸氟替卡松吸入气雾剂,早上吸入2次,晚上吸入2次,经口吸入,每吸125μg。两组每日给药剂量均为500μg,分别于治疗前及治疗12周后统计患者鼻炎症状积分,哮喘控制测试评分,哮喘生存质量评分及肺功能。结果两组患者吸入治疗后鼻炎症状、哮喘控制测试评分及生存质量评分均明显改善,有统计学意义(P<0.05),鼻吸组鼻炎症状改善优于口吸组(P<0.05),口吸组在哮喘控制评分、生存质量评分及肺功能改善方面优于鼻吸组(P<0.05)。结论鼻吸、口吸激素均能明显提高CARAS患者哮喘控制水平,改善生存质量,减少鼻炎症状,但口吸激素对患者鼻炎症状控制不如鼻吸激素,在哮喘控制、提高生存质量、改善肺功能方面优于鼻吸激素。
Objective To investigate the effects of oral and nasal inhalation hormones on clinical symptoms and quality of life in patients with allergic rhinitis-asthmatics syndrome (CARAS). Methods Fifty-five patients with allergic rhinitis-asthma syndrome were randomly divided into two groups, nasal inhalation group (n = 27), fluticasone propionate nasal spray (nostril) twice a day for each nostril and nostril , Each spray 50μg; mouth suction group 28 cases, given fluticasone propionate inhalation aerosol, inhaled in the morning 2 times, inhaled twice a night, inhaled by mouth, each suction 125μg. The daily doses of the two groups were 500μg. The scores of rhinitis symptom score, asthma control test score, asthma quality of life score and pulmonary function were calculated before and 12 weeks after treatment. Results The rhinitis symptom scores, asthma control test scores and quality of life scores were significantly improved after inhalation treatment in both groups (P <0.05). The improvement of rhinitis symptoms in nasal inhalation group was better than that in oral inhalation group (P0.05) Suction group was superior to nasal group in asthma control score, quality of life score and lung function improvement (P <0.05). Conclusion Both nasal and oral inhalation hormones can significantly improve the control of asthma in CARAS patients, improve the quality of life and reduce the symptoms of rhinitis. However, oral hormones are not as good as nasal hormones in controlling rhinitis in asthma control, improving quality of life and improving lung function Better than nasal hormones.